Ubs Group Ag Esperion Therapeutics, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 90,293 shares of ESPR stock, worth $279,908. This represents 0.0% of its overall portfolio holdings.

Number of Shares

90,293

Previous 68,176 32.44%

Holding current value

$279,908

Previous $151,000 1.99%

% of portfolio

0.0%

Previous 0.0%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$1.61 - $2.73 $35,608 - $60,379	22,117 Added 32.44%	90,293 $148,000
Q2 2024 Aug 13, 2024	BUY	$1.84 - $3.24 $86,067 - $151,554	46,776 Added 218.58%	68,176 $151,000
Q1 2024 May 13, 2024	BUY	$2.02 - $3.02 $484 - $724	240 Added 1.13%	21,400 $57,000
Q4 2023 Feb 09, 2024	SELL	$0.73 - $3.08 $7,300 - $30,800	-10,000 Reduced 32.09%	21,160 $63,000
Q3 2023 Nov 09, 2023	SELL	$0.96 - $1.79 $23,080 - $43,035	-24,042 Reduced 43.55%	31,160 $30,000
Q2 2023 Aug 11, 2023	SELL	$1.2 - $1.76 $10,066 - $14,764	-8,389 Reduced 13.19%	55,202 $76,000
Q1 2023 May 12, 2023	BUY	$1.46 - $7.3 $58,589 - $292,949	40,130 Added 171.05%	63,591 $101,000
Q4 2022 Feb 08, 2023	BUY	$5.09 - $8.5 $47,728 - $79,704	9,377 Added 66.58%	23,461 $146,000
Q3 2022 Nov 10, 2022	SELL	$5.45 - $8.13 $12,916 - $19,268	-2,370 Reduced 14.4%	14,084 $95,000
Q2 2022 Aug 10, 2022	BUY	$4.77 - $6.67 $12,449 - $17,408	2,610 Added 18.85%	16,454 $104,000
Q1 2022 May 16, 2022	SELL	$3.34 - $5.56 $169,999 - $282,992	-50,898 Reduced 78.62%	13,844 $64,000
Q4 2021 Feb 14, 2022	BUY	$4.81 - $11.92 $145,387 - $360,293	30,226 Added 87.57%	64,742 $323,000
Q3 2021 Nov 15, 2021	SELL	$11.34 - $21.37 $211,196 - $397,994	-18,624 Reduced 35.05%	34,516 $416,000
Q2 2021 Aug 13, 2021	SELL	$19.4 - $28.71 $260,638 - $385,718	-13,435 Reduced 20.18%	53,140 $1.12 Million
Q1 2021 May 12, 2021	BUY	$25.12 - $36.89 $1.31 Million - $1.93 Million	52,296 Added 366.24%	66,575 $1.87 Million
Q4 2020 Feb 11, 2021	SELL	$24.2 - $35.76 $224,551 - $331,817	-9,279 Reduced 39.39%	14,279 $371,000
Q3 2020 Nov 12, 2020	SELL	$31.18 - $52.71 $1.02 Million - $1.72 Million	-32,690 Reduced 58.12%	23,558 $875,000
Q2 2020 Jul 31, 2020	SELL	$30.04 - $51.31 $906,457 - $1.55 Million	-30,175 Reduced 34.92%	56,248 $2.89 Million
Q1 2020 May 01, 2020	BUY	$27.44 - $73.84 $588,807 - $1.58 Million	21,458 Added 33.03%	86,423 $2.73 Million
Q4 2019 Feb 14, 2020	BUY	$35.4 - $59.82 $1.9 Million - $3.21 Million	53,670 Added 475.17%	64,965 $3.87 Million
Q3 2019 Nov 14, 2019	SELL	$34.47 - $47.53 $118,990 - $164,073	-3,452 Reduced 23.41%	11,295 $414,000
Q2 2019 Aug 14, 2019	SELL	$40.1 - $52.33 $403,967 - $527,172	-10,074 Reduced 40.59%	14,747 $686,000
Q1 2019 May 14, 2019	SELL	$40.11 - $53.57 $6.44 Million - $8.6 Million	-160,621 Reduced 86.62%	24,821 $997,000
Q4 2018 Feb 14, 2019	BUY	$36.99 - $59.11 $4.24 Million - $6.77 Million	114,538 Added 161.54%	185,442 $8.53 Million
Q3 2018 Nov 14, 2018	BUY	$40.74 - $51.41 $1.26 Million - $1.59 Million	30,941 Added 77.42%	70,904 $3.15 Million
Q2 2018 Aug 14, 2018	SELL	$36.2 - $76.4 $2.57 Million - $5.42 Million	-70,919 Reduced 63.96%	39,963 $1.57 Million
Q1 2018 May 15, 2018	BUY	$65.94 - $80.76 $1.78 Million - $2.18 Million	26,975 Added 32.15%	110,882 $8.02 Million
Q4 2017 Feb 14, 2018	SELL	$43.47 - $67.43 $881,745 - $1.37 Million	-20,284 Reduced 19.47%	83,907 $5.52 Million
Q3 2017 Nov 14, 2017	SELL	$43.8 - $52.77 $2.1 Million - $2.53 Million	-47,870 Reduced 31.48%	104,191 $5.22 Million
Q2 2017 Aug 14, 2017	BUY	N/A	50,930 Added 50.36%	152,061 $7.04 Million
Q1 2017 Nov 14, 2017	BUY	N/A	101,131	101,131 $3.57 Million

Others Institutions Holding ESPR

# of Institutions

207

Shares Held

128M

Call Options Held

1.67M

Put Options Held

930K

View Full List

About Esperion Therapeutics, Inc.

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $206M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

More about ESPR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account